Rx DRUG PRICES AT PRODUCER LEVEL GROW 3% IN FIRST QUARTER
Rx DRUG PRICES AT PRODUCER LEVEL GROW 3% IN FIRST QUARTER based on data from the Bureau of Labor Statistics' Producer Price Index. The first quarter increase indicates a moderating trend from 1987 when the first quarter producer price index for prescription drugs increased 4%. Although the December through March producer price figures are still preliminary, the 3% price increase is the smallest first quarter producer price run-up for prescription drugs in the 1980s, according to Bureau of Labor Statistics' data. With drug prices generally increasing 9-11% annually through the 1980s, first quarter producer prices for prescription drugs have historically risen 4% to 4.5%. The exception was 1984, when Rx drug prices at the producer level grew 3.7%. Drug categories showing the biggest first quarter price gains, according to the Bureau of Labor Statistics, were hormones (up 14.4%), CNS stimulants (up 8.7%), Rx cough/cold preparations (up 7.5%), vasodilators (up 6.6%), adult Rx multivitamins (up 6.4%), and Rx analgesics (up 5.3%). Despite showing the biggest price gain during the first quarter, price increases for hormones have not been steady, according to the Bureau of Labor Statistics. If the producer price index for hormones is considered for the four month period from November to March, prices rose only 1.3% Diuretic and anti-arthritic price declines during the first quarter indicated little pricing flexibility in these markets. The Bureau of Labor Statistics' figures show anti-arthritic prices at the manufacturer level falling .7% while diuretic prices edged down .6%.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: